Authors: Urska Bregar Borut Jug Irena Keber Matija Cevc Miran Sebestjen
Publish Date: 2013/05/28
Volume: 29, Issue: 3, Pages: 313-319
Abstract
Raising highdensity lipoprotein cholesterol HDLC is an important strategy for reducing residual cardiovascular risk In the present study we sought to assess the effect of extendedrelease niacin/laropiprant on endothelial function in patients after a myocardial infarction with target lowdensity lipoprotein cholesterol LDLC In this doubleblind placebocontrolled trial 63 men 35–60 years of age after a myocardial infarction were randomized to either niacin/laropiprant 1000/20 mg daily for 4 weeks and 2000/40 mg daily thereafter or placebo Flowmediated dilation FMD and nitroglycerininduced GTN dilation of the brachial artery total cholesterol TC LDLC HDLC triglycerides TG lipoproteina Lpa and apolipoprotein Apo A1/B were measured at baseline and after 12 weeks of intervention FMD significantly increased from 39 ± 51 to 98 ± 44 p 0001 in the niacin/laropiprant group but not in the placebo group 46 ± 44 to 61 ± 44 p = 016 p = 002 for comparison of interventions GTN dilation also increased in the niacin/laropiprant group from 125 ± 61 to 167 ± 48 p = 002 but not in the placebo group 134 ± 50 to 151 ± 52 p = 018 p = 060 for comparison of interventions Niacin/laropiprant reduced TC and LDLC p = 005 for both and increased HDLC p 0001 without influencing TG with no changes in the placebo group Lpa p = 0026 and ApoB p = 0014 were significantly lower in the niacin/laropiprant group with no difference in the placebo group ApoA1 did not change in either of the groups p = 013 p = 026 FMD and GTN dilation improvements did not correlate with changes in the lipid profile Niacin/laropiprant improves endotheliumdependent and endotheliumindependent dilation of the brachial artery This improvement does not correlate with changes in lipid parameters
Keywords: